Loading
The trial that nearly doubled survival in previously treated pancreatic cancer, presented in the ASCO 2026 plenary. The biggest result in the disease's history.
500 patients, 59 sites. Topline 13 April 2026; presented by Brian Wolpin (Dana-Farber) at the ASCO 2026 plenary (31 May) with simultaneous NEJM publication. Median OS 13.2 vs 6.7 months (HR 0.40, p<0.0001); PFS also significantly improved. The NDA (220910) was received by the FDA on 17 July 2026 and approved on 26 August 2026 as Rasonque for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy. First-line (RASolute 303) and adjuvant (RASolute 304) trials follow.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
500 enrolled.
95% CI 5.7 to 7.5 · 95% CI 2.9 to 4.2
Source95% CI 25 to 36 · 95% CI 7 to 15
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Daraxonrasib | - | 13.2 months | 0.4 | - | link |
| Chemotherapy (gemcitabine/nab-paclitaxel or mFOLFOX6) | - | 6.7 months | ||||
| Progression-free survival by blinded independent central review (overall population) | Daraxonrasib | 248 | 7.2 months | 0.49 (0.38 to 0.64) | <0.0001 | link |
| Chemotherapy (mFOLFIRINOX, gemcitabine/nab-paclitaxel, FOLFOX or liposomal irinotecan with 5-FU/LV) | 252 | 3.6 months | ||||
| Objective response rate by blinded independent central review (overall population) | Daraxonrasib | 248 | 30% | - | <0.0001 | link |
| Chemotherapy | 252 | 11% |
One of the most cited trial reports Europe PMC returns for Daraxonrasib in Pancreatic ductal adenocarcinoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
The mechanism that let one drug address G12D, G12V and G12R together, which is why the RASolute 302 trial could enrol unselected pancreatic cancer and nearly double survival.
It is the allele-level prognosis behind reading the KRAS variant rather than 'KRAS mutant', and it shows the older EUS assay over-called wild-type (33%).
Shares Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy, Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib.
Shares RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable, Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib.
Shares Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, KRAS G12C-mutant pancreatic ductal adenocarcinoma, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall.
Shares RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, KRAS & RAS inhibitors, The undruggable drivers.
Shares Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, KRAS & RAS inhibitors.
Shares Covalent chemistry for the RAS mutations that still have no drug, Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers.
Shares Covalent chemistry for the RAS mutations that still have no drug, Off-the-shelf KRAS vaccines after pancreatic cancer surgery, Revolution Medicines, KRAS & RAS inhibitors.
Shares KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma, CodeBreaK 100 (pancreatic cancer cohort), Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression.